Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy, Biologic therapy.

University MedicalCenter Utrecht Cancer Center, Utrecht, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:4City/State/Province:Utrecht
Treatments:Chemotherapy, Biologic therapyHospital:University MedicalCenter Utrecht Cancer Center
Drugs:Journal:Link
Date:Nov 2010

Description:

Patients:
This study involved 26 women with platinum-resistant ovarian cancer. The median age was 60 years.

Treatment:
Patients were treated with the chemotherapy agent pegylated liposomal doxorubicin and the biologic therapy agent atrasentan, which inhibits a protein called ETaR that is involved in cancer cell growth.

Toxicities:
The maximum toxicity level reported was of grade 4 and included nausea/vomiting, mucositis (inflammation of the lining of the GI tract), and headache.

Results:
The median overall survival in this study was 13.1 months.

Support:
This study was supported by Abbot Laboratories, the makers of atrasentan (brand name: Xinlay).

Correspondence: Dr. Petronella O. Witteveen; email: [email protected]



Back